This study is to evaluate the efficacy and safety of \[18F\]-APN-1607 Injection in PET imaging for detecting AD-related cognitive impairment.
Subjects must be able to understand and voluntarily sign a written informed consent form (ICF);
Age ≥ 50 years, regardless of gender;
Subjects with HV, MCI, and AD should meet the clinical diagnostic criteria
Can tolerate brain MRI and PET imaging examinations;
Specific clinical phenotypes of atypical AD as defined in the 2014 IWG-2 criteria
Possible presence of frontotemporal degeneration (FTLD), characterized by progressive psych behavioral abnormalities and executive dysfunction，Characterized primarily by impairment and language function, progressive aphasia
The core symptoms of Lewy body dementia include fluctuating cognitive changes accompanied by significant attention and arousal abnormalities, recurrent typical visual hallucinations, and spontaneous symptoms of Parkinson's syndrome;
Currently suffering from significant mental illness. Subjects with accompanying psychiatric symptoms need to be carefully evaluated by the researchers to determine whether they can complete the imaging process;